Market Access Views from Asembia: EVERSANA's take on outsourcing, AI, and ... Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.
News Ireland's Mallinckrodt closes spinout, rebrands as Keenova Two new pharma companies - Keenova and Par Health - have now emerged from the merger of Mallinckrodt and Endo earlier this year.
Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.